RUNX3 site-specific hypermethylation predicts papillary thyroid cancer recurrence

American Journal of Cancer Research

Volumn 4, Issue 6, 2014, Pages 725-737

  Wang, Dan ^a   Cui, Wei ^a   Wu, Xiaoyan ^a   Qu, Yiping ^a   Wang, Na ^a   Shi, Bingyin ^a   Hou, Peng ^a  

^a THE FIRST AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

Author keywords

Papillary thyroid cancer (PTC); Promoter hypermethylation; Pyrosequencing; RUNX3; Tumor recurrence

Indexed keywords

B RAF KINASE; DEATH ASSOCIATED PROTEIN KINASE; GENOMIC DNA; RETINOIC ACID RECEPTOR BETA; TRANSCRIPTION FACTOR RUNX3; UVOMORULIN;

ADULT; ARTICLE; BRAF GENE; CANCER RECURRENCE; CANCER TISSUE; CDH1 GENE; CONTROLLED STUDY; CPG ISLAND; DAPK GENE; DNA ISOLATION; DNA METHYLATION; FEMALE; GENE MUTATION; GOITER; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PREDICTION; PROMOTER REGION; PYROSEQUENCING; RARBETA GENE; RUNX3 GENE; THYROID GLAND; THYROID PAPILLARY CARCINOMA;

EID: 84955515785     PISSN: None     EISSN: 21566976     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Xing M. Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer 2013; 13: 184-99.
2. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014; 64: 9-29.
3. Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995 [see commetns]. Cancer 1998; 83: 2638-48.
4. Xing M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev 2007; 28: 742-62.
5. Xing M. Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer 2013; 13: 184-99.
6. Kim TY, Kim WB, Rhee YS, Song JY, Kim JM, Gong G, Lee S, Kim SY, Kim SC, Hong SJ, Shong YK. The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma. Clin Endocrinol (Oxf) 2006; 65: 364-8.
7. Pelttari H, Schalin-Jäntti C, Arola J, Löyttyniemi E, Knuutila S, Välimäki MJ. BRAFV600E mutation does not predict recurrence after long-term follow-up in TNM stage I or II papillary thyroid carcinoma patients. APMIS 2012; 120: 380-6.
8. Xing M. Gene methylation in thyroid tumorigenesis. Endocrinology 2007; 148: 948-53.
9. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007; 128: 683-92.
10. McCabe MT, Brandes JC, Vertino PM. Cancer DNA methylation: molecular mechanisms and clinical implications. Clin Cancer Res 2009; 15: 3927-37.
11. Zhao Y, Guo S, Sun J, Huang Z, Zhu T, Zhang H, Gu J, He Y, Wang W, Ma K, Wang J, Yu J. Methylcap-seq reveals novel DNA methylation markers for the diagnosis and recurrence prediction of bladder cancer in a Chinese population. PLoS One 2012; 7: e35175.
12. Harada H, Miyamoto K, Yamashita Y, Nakano K, Taniyama K, Miyata Y, Ohdan H, Okada M. Methylation of breast cancer susceptibility gene 1 (BRCA1) predicts recurrence in patients with curatively resected stage I non-small cell lung cancer. Cancer 2013; 119: 792-8.
13. Haldrup C, Mundbjerg K, Vestergaard EM, Lamy P, Wild P, Schulz WA, Arsov C, Visakorpi T, Borre M, Høyer S, Orntoft TF, Sørensen KD. DNA methylation signatures for prediction of biochemical recurrence after radical prostatectomy of clinically localized prostate cancer. J Clin Oncol 2013; 31: 3250-8.
14. Kanda M, Nomoto S, Oya H, Takami H, Hibino S, Hishida M, Suenaga M, Yamada S, Inokawa Y, Nishikawa Y, Asai M, Fujii T, Sugimoto H, Kodera Y. Downregulation of DENND2D by promoter hypermethylation is associated with early recurrence of hepatocellular carcinoma. Int J Oncol 2014; 44: 44-52.
15. Shi J, Zhang G, Yao D, Liu W, Wang N, Ji M, He N, Shi B, Hou P. Prognostic significance of aberrant gene methylation in gastric cancer. Am J Cancer Res 2012; 2: 116-29.
16. Zhang B, Liu S, Zhang Z, Wei J, Qu Y, Wu K, Yang Q, Hou P, Shi B. Analysis of BRAF(V600E) mutation and DNA methylation improves the diagnostics of thyroid fine needle aspiration biopsies. Diagn Pathol 2014; 9: 45.
17. Hu S, Liu D, Tufano RP, Carson KA, Rosenbaum E, Cohen Y, Holt EH, Kiseljak-Vassiliades K, Rhoden KJ, Tolaney S, Condouris S, Tallini G, Westra WH, Umbricht CB, Zeiger MA, Califano JA, Vasko V, Xing M. Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancer. Int J Cancer 2006; 119: 2322-9.
18. Hoque MO, Rosenbaum E, Westra WH, Xing M, Ladenson P, Zeiger MA, Sidransky D, Umbricht CB. Quantitative assessment of promoter methylation profiles in thyroid neoplasms. J Clin Endocrinol Metab 2005; 90: 4011-8.
19. Hou P, Liu D, Xing M. Genome-wide alterations in gene methylation by the BRAF V600E mutation in papillary thyroid cancer cells. Endocr Relat Cancer 2011; 18: 687-97.
20. Brait M, Loyo M, Rosenbaum E, Ostrow KL, Markova A, Papagerakis S, Zahurak M, Goodman SM, Zeiger M, Sidransky D, Umbricht CB, Hoque MO. Correlation between BRAF mutation and promoter methylation of TIMP3, RARβ2 and RASSF1A in thyroid cancer. Epigenetics 2012; 7: 710-9.
21. Kampfrath T, Levinson SS. Brief critical review: Statistical assessment of biomarker performance. Clin Chim Acta 2013; 419: 102-7.
22. Caron NR, Clark OH. Well differentiated thyroid cancer. Scand J Surg 2004; 93: 261-71.
23. Xing M, Haugen BR, Schlumberger M. Progress in molecular-based management of differentiated thyroid cancer. Lancet 2013; 381: 1058-69.
24. Woodrum DT, Gauger PG. Role of 131I in the treatment of well differentiated thyroid cancer. J Surg Oncol 2005; 89: 114-21.
25. Mazzaferri EL. Management of low-risk differentiated thyroid cancer. Endocr Pract 2007; 13: 498-512.
26. Molinaro E, Pieruzzi L, Viola D. Radioiodine post-surgical remnant ablation in patients with differentiated thyroid cancer: news from the last 10 years. J Endocrinol Invest 2012; 35: 16-20.
27. Frasoldati A, Pesenti M, Gallo M, Caroggio A, Salvo D, Valcavi R. Diagnosis of neck recurrences in patients with differentiated thyroid carcinoma. Cancer 2003; 97: 90-6.
28. Pacini F, Molinaro E, Castagna MG, Agate L, Elisei R, Ceccarelli C, Lippi F, Taddei D, Grasso L, Pinchera A. Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma. J Clin Endocrinol Metab 2003; 88: 3668-73.
29. Whitley RJ, Ain KB. Thyroglobulin: a specific serum marker for the management of thyroid carcinoma. Clin Lab Med 2004; 24: 29-47.
30. Spencer CA. Challenges of serum thyroglobulin (Tg) measurement in the presence of Tg autoantibodies. J Clin Endocrinol Metab 2004; 89: 3702-4.
31. Ito Y, Higashiyama T, Takamura Y, Miya A, Kobayashi K, Matsuzuka F, Kuma K, Miyauchi A. Risk factors for recurrence to the lymph node in papillary thyroid carcinoma patients without preoperatively detectable lateral node metastasis: validity of prophylactic modified radical neck dissection. World J Surg 2007; 31: 2085-91.
32. Hsu YT, Gu F, Huang YW, Liu J, Ruan J, Huang RL, Wang CM, Chen CL, Jadhav RR, Lai HC, Mutch DG, Goodfellow PJ, Thompson IM, Kirma NB, Huang TH. Promoter hypomethylation of EpCAM-regulated bone morphogenetic protein gene family in recurrent endometrial cancer. Clin Cancer Res 2013; 19: 6272-85.
33. Stott-Miller M, Zhao S, Wright JL, Kolb S, Bibikova M, Klotzle B, Ostrander EA, Fan JB, Feng Z, Stanford JL. Validation study of genes with hypermethylated promoter regions associated with prostate cancer recurrence. Cancer Epidemiol Biomarkers Prev 2014; 23: 1331-9.
34. Su SF, de Castro Abreu AL, Chihara Y, Tsai Y, Andreu-Vieyra C, Daneshmand S, Skinner EC, Jones PA, Siegmund KD, Liang G. A panel of three markers hyper-and hypomethylated in urine sediments accurately predicts bladdercancer recurrence. Clin Cancer Res 2014; 20: 1978-89.
35. Mancikova V, Buj R, Castelblanco E, Inglada-Pérez L, Diez A, de Cubas AA, Curras-Freixes M, Maravall FX, Mauricio D, Matias-Guiu X, Puig-Domingo M, Capel I, Bella MR, Lerma E, Castella E, Reverter JL, Peinado Má, Jorda M, Robledo M. DNA methylation profiling of well-differentiated thyroid cancer uncovers markers of recurrencefree survival. Int J Cancer 2014; 135: 598-610.
36. Czarnecka K, Pastuszak-Lewandoska D, Migdalska-Sek M, Nawrot E, Brzezinski J, Dedecjus M, Pomorski L, Brzezianska E. Aberrant methylation as a main mechanism of TSGs silencing in PTC. Front Biosci (Elite Ed) 2011; 3: 137-57.
37. Marsh S. Pyrosequencing applications. Methods Mol Biol 2007; 373: 15-24.
38. Huang G, Krocker JD, Kirk JL, Merwat SN, Ju H, Soloway RD, Wieck LR, Li A, Okorodudu AO, Petersen JR, Abdulla NE, Duchini A, Cicalese L, Rastellini C, Hu PC, Dong J. Evaluation of INK4A promoter methylation using pyrosequencing and circulating cell-free DNA from patients with hepatocellular carcinoma. Clin Chem Lab Med 2014; 52: 899-909.
39. Christofori G, Semb H. The role of the cell-adhesion molecule E-cadherin as a tumour-suppressor gene. Trends Biochem Sci 1999; 24: 73-6.
40. Canel M, Serrels A, Frame MC, Brunton VG. E-cadherin-integrin crosstalk in cancer invasion and metastasis. J Cell Sci 2013; 126: 393-401.
41. Blyth K, Cameron ER, Neil JC. The RUNX genes: gain or loss of function in cancer. Nat Rev Cancer 2005; 5: 376-87.
42. Ko HJ, Kim BY, Jung CH, Chun SW, Mok JO, Kim YJ, Park HK, Kim CH, Kim SJ, Byun DW, Suh KI, Yoo MH, Kang SG. DNA methylation of RUNX3 in papillary thyroid cancer. Korean J Intern Med 2012; 27: 407-10.